These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 28445592)
21. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1). Wäsch R; Hasskarl J; Schnerch D; Lübbert M Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841 [TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related]
23. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers. Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927 [TBL] [Abstract][Full Text] [Related]
25. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192 [TBL] [Abstract][Full Text] [Related]
27. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy. Studach L; Wang WH; Weber G; Tang J; Hullinger RL; Malbrue R; Liu X; Andrisani O J Biol Chem; 2010 Sep; 285(39):30282-93. PubMed ID: 20624918 [TBL] [Abstract][Full Text] [Related]
28. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Hugle M; Belz K; Fulda S Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389 [TBL] [Abstract][Full Text] [Related]
29. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma. Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473 [TBL] [Abstract][Full Text] [Related]
30. Regulation of Hepatitis B Virus Replication by Cyclin Docking Motifs in Core Protein. Liu H; Xi J; Hu J J Virol; 2021 May; 95(12):. PubMed ID: 33789995 [TBL] [Abstract][Full Text] [Related]
31. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Song B; Liu XS; Rice SJ; Kuang S; Elzey BD; Konieczny SF; Ratliff TL; Hazbun T; Chiorean EG; Liu X Mol Cancer Ther; 2013 Jan; 12(1):58-68. PubMed ID: 23188630 [TBL] [Abstract][Full Text] [Related]
32. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer. Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype. Xia Y; Cheng X; Li Y; Valdez K; Chen W; Liang TJ J Virol; 2018 Oct; 92(19):. PubMed ID: 30021897 [TBL] [Abstract][Full Text] [Related]
34. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. Shin SB; Woo SU; Yim H J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351 [TBL] [Abstract][Full Text] [Related]
35. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. Burkard ME; Santamaria A; Jallepalli PV ACS Chem Biol; 2012 Jun; 7(6):978-81. PubMed ID: 22422077 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells. Yunoki T; Tabuchi Y; Hayashi A; Kondo T Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665 [TBL] [Abstract][Full Text] [Related]
37. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
38. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761 [TBL] [Abstract][Full Text] [Related]
39. PLK1 down-regulates parainfluenza virus 5 gene expression. Sun D; Luthra P; Li Z; He B PLoS Pathog; 2009 Jul; 5(7):e1000525. PubMed ID: 19629176 [TBL] [Abstract][Full Text] [Related]
40. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]